RxSight stock falls as price targets are cut

Published on 09/22/2026 at 21:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RxSight stock traded at USD 5.06 on September 22, 2026, after Jefferies cut its target to USD 5.75. Quarterly revenue reached USD 33.74 million.

RXST, US78419L1008, Illustration mit AI erstellt.

RxSight stock traded at USD 5.06 on Nasdaq on September 22, 2026, down USD 0.08 from the previous close, while the company carried a market capitalization of USD 210.28 million. The move came as Jefferies Financial Group reduced its price objective from USD 6.50 to USD 5.75 and kept a Hold rating, according to MarketBeat.

Targets remain below earlier levels

The analyst reset adds to a mixed but cautious view of the medical technology company. MarketBeat reported on September 22, 2026, that Bank of America lowered its target from USD 6.50 to USD 5.50 and assigned an Underperform rating. The same report put the average analyst rating at Reduce and the consensus price target at USD 8.26.

The spread between the USD 5.50 Bank of America target and the USD 8.26 consensus target is USD 2.76, showing how widely expectations differ. Jefferies' USD 5.75 target is also below that consensus, while the stock remains below its 50-day moving average of USD 6.12 and its 200-day moving average of USD 6.14, both reported on September 22, 2026.

Revenue beats estimates but losses persist

RxSight's latest reported quarter, released on August 5, 2026, produced revenue of USD 33.74 million versus a consensus estimate of USD 32.55 million. That USD 1.19 million beat was accompanied by a quarterly loss of USD 0.29 per share, compared with the expected loss of USD 0.33 per share, according to MarketBeat.

The operating picture therefore combines a measurable revenue beat with continuing losses. The reported net margin was negative 36.80 percent for that quarter, while analysts surveyed in the report expected full-year 2026 EPS of negative USD 1.01. For investors, the key tension is the contrast between revenue above estimates and a business that has not yet reached profitability.

Stock remains near its yearly low

The September 22, 2026 market snapshot placed RXST between its 52-week low of USD 4.48 and its 52-week high of USD 13.22. At USD 5.06, the stock stood USD 0.58 above the low and USD 8.16 below the high, while the reported trading volume was 81,635 shares against an average volume of 948,525 shares.

RxSight develops the Light Adjustable Lens and Light Delivery Device for cataract procedures, allowing surgeons to adjust vision after implantation through controlled ultraviolet-light treatments, according to MarketBeat. The commercial opportunity depends on continued adoption of the technology, while the negative margin and analyst target reductions keep execution and cash generation central to the valuation.

RXST closes at USD 5.06

RxSight stock traded at USD 5.06 on Nasdaq on September 22, 2026, with a reported daily decline of USD 0.08. The 52-week range was USD 4.48 to USD 13.22, and market capitalization was USD 210.28 million as of the same market snapshot.